Allogene Therapeutics, Inc.
- ALLO
- NASDAQ
- Biotechnology
- Allogeneic CAR-T
- Immuno-Oncology
- Cell Therapy
$1.31
Today −0.36%Quote Oct 19, 2026, 03:24 PM UTC
−24.28%over the last month
Max drawdown −25.4%From 1-month high −24.3%3 months −26.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$451.0M
Quote Oct 19
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$26.53
+1932.5% from here
Floor
$1.28
2.2% below price
Where the price sits
30 analysts
Analyst range, low to high
$3.85$55.00
- Price $1.31
- Resistance $1.30
- Consensus $26.53
Analysts' average target sits about 1932% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALLOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
151
Founded
2017